• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

4.750 -0.010 (-0.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week
September 05, 2023
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD. 
Via Talk Markets
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
September 05, 2023
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15%
September 02, 2023
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD. 
Via Talk Markets
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
August 28, 2023
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
Via Benzinga
The Latest Analyst Ratings for Compass Pathways
August 22, 2023
Via Benzinga
3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street
August 26, 2023
These cutting-edge biotech stocks could deliver life-changing gains for early shareholders. 
Via The Motley Fool
6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week
August 25, 2023
Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week. 
Via Talk Markets
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
August 21, 2023
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend
August 20, 2023
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... 
Via Talk Markets
COMPASS' Securities Purchase Agreement Is Big News
August 18, 2023
It’s still cannabis earnings season, but we’re also turning to look at some of the news from the psychedelics industry. ... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Up To $285M In Financing: COMPASS Pathways' Private Placement Backed By 'Select Group' Of Investors
August 16, 2023
Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group of... 
Via Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index
August 13, 2023
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. 
Via Talk Markets
Atai's Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline's Psilocybin, DMT, Ketamine & MDMA
August 10, 2023
Atai Life Sciences (NASDAQ: ATAI) reported its consolidated, unaudited financial results for the second quarter 2023 ended June 30. Numbers show: 
Via Benzinga
Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript
August 04, 2023
CMPS earnings call for the period ending June 30, 2023. 
Via The Motley Fool
COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady Quarter And 'Strong Progress Across The Business'
August 03, 2023
Psychedelics biotech COMPASS Pathways’ (NASDAQ: CMPS) consolidated unaudited financial results for the second quarter 2023, ended June 30 are as follows: 
Via Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
August 03, 2023
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average
July 30, 2023
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July: 
Via Talk Markets
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
July 28, 2023
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock
July 28, 2023
For biotechs developing psychedelic therapies, good news comes in many forms. 
Via The Motley Fool
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
July 26, 2023
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia
Compass' Psilocybin Therapy Proves Helpful In Treating Anorexia: Clinical Trial Shows
July 25, 2023
UC-San Diego authors assessed psilocybin therapy’s potential as a treatment for anorexia nervosa. They recently shared what are believed to be the first results from such a research study, and the... 
Via Benzinga
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
July 25, 2023
By Rachael Green, Benzinga 
Via TheNewswire.com
Exposures Product Safety
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
July 25, 2023
--News Direct-- 
Via News Direct
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
July 24, 2023
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal... 
Via Benzinga
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
July 24, 2023
The American Medical Association’s (AMA) Panel recently released the full details of a new code for psychological support during the administration of psychedelic treatments. 
Via Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD
July 23, 2023
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug... 
Via Talk Markets
Jim Cramer Says It's Time To Buy This Financial Services Stock Down 32% YTD
July 21, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Illumina, Inc. (NASDAQ: ILMN) is not even as good as Danaher Corporation (NYSE: DHR). 
Via Benzinga
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
July 18, 2023
COMPASS Pathways (NASDAQ: CMPS) shared results from an open-label Phase 2 trial assessing its synthetic psilocybin COMP360 alongside SSRIs for Treatment-Resistant Depression (TRD.) 
Via Benzinga
Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD
July 14, 2023
Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap